Evaluation of antimicrobial photodynamic therapy and doxycycline during supportive periodontal therapy

Clinical and microbiological evaluation of local doxycycline and antimicrobial photodynamic therapy during supportive periodontal therapy: a randomized clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN17209965

Enrollment

105

Registered

2021-02-24

Start date

2015-10-01

Completion date

Unknown

Last updated

2023-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent/recurrent periodontal pockets of patients with periodontal disease Oral Health Periodontal disease, unspecified

Interventions

Periodontitis patients enrolled in supportive periodontal therapy are randomly treated as follows: Group A (n=35): subgingival instrumentation (SI) + photodynamic therapy (PDT) and 7 d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Minimum age 25 years 2. Patients should be enrolled in a regular maintenance program (after completion of active periodontal therapy) 3. Diagnoses of chronic periodontitis 4. Minimum one site per quadrant with PD =4 mm and BOP+ 5. Good level of oral hygiene [plaque control record (PCR) after O’Leary 1972 =30%] 6. Systemically healthy: no history of diseases that may influence the severity or progression of the periodontal disease (Down syndrome, HIV, diabetes mellitus type 1 and 2), post-irradiation in the head and neck area, infectious diseases or heart diseases that need a prophylactic antibiosis before dental treatments, liver diseases 7. Informed written consent

Exclusion criteria

Exclusion criteria: 1. Systemic or local use of antibiotics within the preceding 3 months 2. Medication that may interact with doxycyclin (e.g., coumarin derivates, containing alcohol derivates, 5-fluorouracil/ disulfiram derivates, amprenavir oral solutions, lopinavir/ritonavir oral solution) 3. Medication that may influence the periodontium: cyclosporin A, compounds of phenytoin, calcium channel blockers (nifedipine, verapamil, amlodipine, diltiazem) 4. Pregnancy or lactation 5. Patients who don’t match the inclusion criteria

Design outcomes

Primary

Measure	Time frame
Number of bleeding sites measured with a mm-scaled periodontal probe and noted on patient files at baseline prior to therapy and at 3, 6 and 12 months	—

Secondary

Measure	Time frame
Measured at baseline prior to therapy and at 3, 6 and 12 months: 1. Probing pocket depth measured with a mm-scaled periodontal probe and noted on patient files 2. Clinical attachment level measured with a mm-scaled periodontal probe and noted on patient files 3. Bleeding indexes measured with a mm-scaled periodontal probe and noted on patient files 4. Plaque indexes assessed dichotomously on patient data sheets after plaque coloration with a disclosing dye 5. Periodontal pathogens measured using real-time PCR 6. Immunomarkers from the sulcus measured using ELISA test	—

Measure

Time frame

Measured at baseline prior to therapy and at 3, 6 and 12 months: 1. Probing pocket depth measured with a mm-scaled periodontal probe and noted on patient files 2. Clinical attachment level measured with a mm-scaled periodontal probe and noted on patient files 3. Bleeding indexes measured with a mm-scaled periodontal probe and noted on patient files 4. Plaque indexes assessed dichotomously on patient data sheets after plaque coloration with a disclosing dye 5. Periodontal pathogens measured using real-time PCR 6. Immunomarkers from the sulcus measured using ELISA test

—

Countries

Romania

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026